Healthcare [ 12/13 ] | Medical Devices [ 109/164 ]
NYSE | Common Stock
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands.
In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products.
Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.
The company sells its products through direct sales organizations and distributors.
Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.41 Increased by +78.26% | 0.38 Increased by +7.89% |
| Feb 22, 24 | 0.76 Increased by +375.00% | 0.70 Increased by +8.57% |
| Nov 2, 23 | 0.67 Increased by +6.60 K% | 0.45 Increased by +48.89% |
| Aug 1, 23 | 0.43 Increased by +4.20 K% | 0.28 Increased by +53.57% |
| May 2, 23 | 0.23 Increased by +2.40 K% | 0.11 Increased by +109.09% |
| Feb 23, 23 | 0.16 Increased by +60.00% | 0.15 Increased by +6.67% |
| Nov 3, 22 | 0.01 Decreased by -91.67% | 0.01 |
| Aug 4, 22 | 0.01 Decreased by -95.24% | -0.03 Increased by +133.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 278.65 M Increased by +15.43% | 11.00 M Increased by +28.50% | Increased by +3.95% Increased by +11.32% |
| Dec 31, 23 | 284.68 M Increased by +28.69% | 54.22 M Increased by +1.30 K% | Increased by +19.05% Increased by +986.70% |
| Sep 30, 23 | 270.95 M Increased by +26.80% | 9.21 M Increased by +505.72% | Increased by +3.40% Increased by +419.97% |
| Jun 30, 23 | 261.50 M Increased by +25.51% | 18.96 M Increased by +614.24% | Increased by +7.25% Increased by +509.71% |
| Mar 31, 23 | 241.40 M Increased by +18.39% | 8.56 M Increased by +10.74 K% | Increased by +3.55% Increased by +9.05 K% |
| Dec 31, 22 | 221.22 M Increased by +8.43% | 3.88 M Increased by +115.74% | Increased by +1.75% Increased by +114.51% |
| Sep 30, 22 | 213.68 M Increased by +12.39% | -2.27 M Decreased by -125.66% | Decreased by -1.06% Decreased by -122.83% |
| Jun 30, 22 | 208.34 M Increased by +13.07% | -3.69 M Decreased by -139.94% | Decreased by -1.77% Decreased by -135.32% |